Electromed, Inc. Form 10-Q Summary
Reporting period: Quarterly and year-to-date periods ended March 31, 2017. The filing is a fiscal 2017 third-quarter report; the supplied metadata refers to “2016 Q3,” which does not match the filing period.
Business Context and Reporting Period
Electromed develops, manufactures and markets airway-clearance products using High Frequency Chest Wall Oscillation technology, principally the SmartVest system. Products are sold in U.S. home-care and institutional markets and internationally through direct sales and distributors. The company operates in one industry segment.
The financial statements are unaudited interim statements prepared under U.S. GAAP. Interim results are not necessarily indicative of full-year results.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2017 | Three Months Ended March 31, 2016 | Nine Months Ended March 31, 2017 | Nine Months Ended March 31, 2016 |
|---|---|---|---|---|
| Net revenues | $6.670 million | $6.036 million | $18.587 million | $17.299 million |
| Gross profit | $5.313 million | $4.627 million | $14.567 million | $13.385 million |
| Gross margin | 79.7% | 76.7% | 78.4% | 77.4% |
| Operating income | $1.037 million | $0.736 million | $2.055 million | $2.570 million |
| Operating margin | 15.5% | 12.2% | 11.1% | 14.9% |
| Net income | $0.648 million | $0.467 million | $1.283 million | $1.875 million |
| Net margin | 9.7% | 7.7% | 6.9% | 10.8% |
| Diluted EPS | $0.08 | $0.06 | $0.15 | $0.23 |
- Revenue mix: Nine-month home-care revenue was $16.712 million, institutional revenue was $1.388 million, and international revenue was $0.487 million.
- Cash and liquidity: Cash was $5.402 million at March 31, 2017, compared with $5.123 million at June 30, 2016. Working capital was approximately $14.642 million.
- Cash flow: Nine-month operating cash flow was $0.806 million, compared with $1.670 million in the prior-year period. Investing cash use was $0.486 million, primarily capital expenditures of $0.426 million and patent costs of $0.060 million. Financing cash use was $0.041 million.
- Debt: The company had approximately $1.166 million of term-loan principal outstanding, with $1.159 million of debt reported on the balance sheet after current maturities and debt issuance costs. No revolving credit balance was outstanding.
- Credit availability: The company had the full $2.5 million revolving line available at March 31, 2017. The line expires December 18, 2017, if not renewed. The term loan bears interest at 3.88% and has a final payment of approximately $1.085 million due December 18, 2018.
- Balance sheet: Total assets were $21.898 million and shareholders’ equity was $18.015 million at March 31, 2017.
Material Changes Versus the Prior Comparable Period
- Third-quarter revenue increased 10.5%, driven primarily by a 13.5% increase in home-care revenue. Nine-month revenue increased 7.4%.
- Third-quarter gross margin improved by 300 basis points, primarily because of higher domestic home-care revenue and lower SmartVest SQL manufacturing costs. Nine-month gross margin improved by 100 basis points.
- Third-quarter operating income increased 40.9% and net income increased 38.8%.
- Nine-month operating income declined 20.1% and net income declined 31.6%, primarily because of higher sales and administrative payroll, higher travel expenses, increased research and development costs, and the absence of the prior-year tax benefit.
- SG&A increased 10.2% in the quarter and 12.7% year to date, reflecting additional sales and administrative personnel, sales incentives, salary increases, share-based compensation and higher travel costs.
- Research and development expense increased to $0.532 million for the nine-month period from $0.183 million, primarily related to development of wireless connectivity for the company’s HFCWO device.
- Operating cash flow declined year over year, mainly because of a $1.322 million increase in accounts receivable and a $0.323 million reduction in accounts payable and accrued liabilities.
- International revenue declined 35.4% in the quarter and 17.6% year to date, reflecting distributor-purchase timing and other international market fluctuations.
Guidance, Outlook, Risks, Contingencies and Unusual Items
- Management expected to launch the new wireless connectivity feature by the end of fiscal 2017 and indicated that R&D expense should decline over the following quarters after most project work was completed.
- Management believed existing working capital and available credit would provide adequate liquidity for the next year.
- Nine-month home-care revenue included a one-time approximately $0.212 million repayment to a state Medicaid program following a reinterpretation of reimbursement rules. Management stated that it did not believe the event reflected other state Medicaid processes.
- The prior-year nine-month period benefited from approximately $0.250 million of revenue from processing a backlog of referrals after a state license was reinstated.
- The company recorded approximately $0.111 million of expense for abandoning certain patents, primarily patents redundant to later SmartVest SQL filings or related to outdated technology.
- The nine-month 2016 effective tax rate benefited from a $0.294 million discrete tax benefit related primarily to releasing a valuation allowance on deferred tax assets. The nine-month 2017 effective tax rate was 36.3%, compared with 25.5% in the prior-year period.
- The company was in compliance with its debt covenants at March 31, 2017. Covenants include a minimum tangible net worth of $10.125 million and restrictions on additional debt and dividends. A future default could permit acceleration of debt and restrict access to financing.
- Key risks include changes to Medicare, Medicaid and private-insurance reimbursement; regulatory and medical-device requirements; competition; international expansion; intellectual-property protection; credit-line renewal; and general economic conditions.
- The company had no off-balance-sheet arrangements and reported no known undisclosed litigation expected to have a material adverse effect.
Important Facts for Investors to Verify
- Confirm the correct reporting period: the filing covers the quarter ended March 31, 2017, not 2016 Q3.
- Assess whether home-care referral and approval growth can offset reimbursement pressure and the prior-year backlog comparison.
- Monitor accounts receivable growth and the decline in operating cash conversion.
- Verify renewal of the $2.5 million revolving line before its December 18, 2017 expiration.
- Evaluate the effect of higher sales-force costs, share-based compensation and travel expenses on full-year margins.
- Track the launch, commercialization and costs of the wireless connectivity feature.
- Review exposure to reimbursement-policy changes, warranty obligations, patent matters and debt-covenant requirements.